Literature DB >> 1532323

Is ondansetron a less effective antiemetic against moderately emetic as compared with highly emetic chemotherapy?

J W Dundee1, C M McMillan, J Yang, P M Wright.   

Abstract

The severity of sickness in the first 5 days after cancer chemotherapy was compared in patients who had or had not received ondansetron 8 mg three times daily. Patients were divided into those having highly emetic chemotherapy, irrespective of gender and women having moderately emetic drugs. Ondansetron appeared to be more effective in the former group.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1532323      PMCID: PMC1381310          DOI: 10.1111/j.1365-2125.1992.tb04027.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  2 in total

1.  Ondansetron as an antiemetic.

Authors:  M D Reed
Journal:  Br J Clin Pharmacol       Date:  1992-08       Impact factor: 4.335

Review 2.  Ondansetron: a pharmacoeconomic and quality-of-life evaluation of its antiemetic activity in patients receiving cancer chemotherapy.

Authors:  G L Plosker; R J Milne
Journal:  Pharmacoeconomics       Date:  1992-10       Impact factor: 4.981

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.